COVID-19 and the Developement of Phobic Fears of Disease

Sponsor

Medical University of Graz (Other)

Overall Status

Recruiting

CT.gov ID

NCT04359121

Collaborator

(none)

600

Enrollment

Location

Anticipated Duration (Months)

17.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

A lot of people suffer from phobias. Phobias concerning certain diseases are not rare. This study will examine whether the COVID-19 (Coronavirus Disease) crisis was able to rise phobias in people and if those with preexisting phobias or fears were more likely to develop a phobia concerning COVID. It will look at different subtypes - physicians, medical staff, general public (not medically affiliated) and patients with psychiatric disorders.

Condition or Disease	Intervention/Treatment	Phase
COVID19	Other: Questionnaires for specific phobia

Study Design

Study Type:

Observational

Anticipated Enrollment :

600 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

COVID-19 and the Developement of Phobic Fears of Disease

Actual Study Start Date :

Dec 15, 2020

Anticipated Primary Completion Date :

Nov 15, 2023

Anticipated Study Completion Date :

Nov 15, 2023

Arms and Interventions

Arm	Intervention/Treatment
Physicians Questionnaires	Other: Questionnaires for specific phobia Questionnaires will be used.
Medical staff Questionnaires	Other: Questionnaires for specific phobia Questionnaires will be used.
General public Questionnaires	Other: Questionnaires for specific phobia Questionnaires will be used.
Patients with psychiatric disorders Questionnaires	Other: Questionnaires for specific phobia Questionnaires will be used.

Outcome Measures

Primary Outcome Measures

Development of phobias [2 years]
Specific Phobia Questionnaire (SPQ): The SPQ consists of 43 items, each rated using a 5-point Likert scale on two dimensions: (1) level of fear, with scores ranging from 0 (no fear) to 4 (extreme fear) and (2) extent to which the fear interferes with one's daily life, with scores ranging from 0 (no interference) to 4 (extreme interference). The SPQ is scored by combining fear ratings of each Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) specific phobia type. Severity Measure for Specific Phobia-Adult: The total score can range from 0 to 40 with higher scores indicating greater severity of specific phobia.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 90 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Person gives written consent
Persons between 18-90 years of age (men and women)
No positive COVID infection known at time of first examination

Exclusion Criteria:

Dementia, Delirium (not able to give consent)
Not fulfilling the inclusion criteria
COVID infection known at first examination point

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Medical University of Graz	Graz	Styria	Austria	8036

Sponsors and Collaborators

Medical University of Graz

Investigators

Principal Investigator: Andreas Baranyi, Prof., Medical University of Graz

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Medical University of Graz

ClinicalTrials.gov Identifier:

NCT04359121

Other Study ID Numbers:

32-354 ex 19/20

First Posted:

Apr 24, 2020

Last Update Posted:

Oct 6, 2021

Last Verified:

Sep 1, 2021

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Additional relevant MeSH terms:

COVID-19

Study Results

No Results Posted as of Oct 6, 2021